Miles D. White, CEO
Thomas C. Freyman, CFO
Mary Sezla, Sr. VP-Global Strategic Mktg. & Svcs.
Stephen R. Fussell, Sr. VP-Human Resources
John M. Leonard, Sr. VP-Pharmaceuticals R&D
Laura J. Schumacher, General Counsel/Exec. VP/Sec.
Richard W. Ashley, Exec. VP-Corp. Dev.
Melissa Brotz, VP-External Comm.
Thomas C. Freyman, Exec. VP-Finance
John C. Landgraf, Exec. VP-Global Nutrition
Richard A. Gonzalez, Exec. VP-Pharmaceuticals/Pres., Abbott Ventures
John M. Capek, Exec. VP-Medical Devices
Edward L. Michael, Exec. VP-Diagnostics Prod.
Miles D. White, Chmn.
David Forrest, Sr. VP-Int'l Nutrition
Phone:
847-937-6100
Fax:
847-937-9555
Toll-Free:
Address:
100 Abbott Park Rd.
Abbott Park, IL 60064 US
GROWTH PLANS/SPECIAL FEATURES
Abbott Laboratories develops, manufactures and sells healthcare products and technologies ranging from pharmaceuticals to medical devices marketed in over 130 countries. It operates in four segments: pharmaceutical products, diagnostics products, nutritional products and vascular products. The pharmaceutical segment deals with adult and pediatric conditions such as rheumatoid arthritis, HIV, epilepsy and manic depression. Its products are spilt into two categories: proprietary pharmaceuticals, which include Humira for the treatment of arthritis, Aluvia for the treatment of HIV and Synthroid for hypothyroidism; and established pharmaceuticals, such as Influvac flu vaccines and Brufen pain and fever relievers. The diagnostic products segment develops systems and tests to diagnose infectious diseases, cancer, diabetes and genetic conditions, including the Commander immunoassay system, ARCHITECT chemistry system and i-STAT hematology systems, which are marketed to hospitals, laboratories, physicians’ offices and plasma protein therapeutic companies. The nutritional products segment offers consumer products such as Similac, Ensure, PediaSure and Zone Perfect, as well as feeding devices in healthcare institutions. The vascular products segment consists of coronary, endovascular and vessel closure devices used in the treatment of vascular disease. Products include the Multi-Link Vision coronary metallic stents, TREK and Voyager balloon dilatation systems and StarClose vessel closure devices. These products are generally marketed and sold directly to hospitals from Abbot-owned distribution centers and public warehouses. The company’s other products include the FreeStyle line of diabetes products, as well as medical devices and products for eye care. In October 2011, Abbott announced plans to separate into two publicly traded companies, one in diversified medical products, which will retain the Abbott name, and the other in research-based pharmaceuticals. In March 2012, the firm disclosed plans to build a nutrition manufacturing facility in Tipp City, Ohio. Employees are offered medical, dental and vision insurance; flexible spending accounts; adoption assistance; an employee assistance program; legal services; tuition assistance; and life insurance.
FINANCIALS: Sales and profits are in thousands of dollars-add 000 to get the full
amount. Yr. 2010 note: Fiscal 2010 results were not available for all companies
at press time.
- 2010 Sales: $35,166,721
- 2009 Sales: $30,764,707
- 2008 Sales: $29,527,552
- 2007 Sales: $25,914,200
- 2006 Sales: $22,476,322
- 2010 Profits: $4,626,172
- 2009 Profits: $5,745,838
- 2008 Profits: $4,880,719
- 2007 Profits: $3,606,300
- 2006 Profits: $1,716,755
Stock Ticker: ABT
Employees: 91000
Fiscal Year Ends: 12/31